Trial · NCT00446563
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI) | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI | Baseline to week 52 | Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat. |
| Secondary | Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI | Baseline to week 52 | |
| Secondary | Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP) | Baseline to week 52 | |
| Secondary | Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP) | Baseline to week 52 | |
| Secondary | Percentage of Participants Achieving Target Blood Pressure at Week 52 | Week 52 | Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \< 90 mm Hg. |
| Secondary | Percentage of Participants Who Experienced Adverse Events (AEs) | Baseline to week 52 | An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00446563/registered